


Preeclampsia Diagnostics Market Size, Share, Industry Growth Analysis, Trends, Forecasts, 2031

Global Preeclampsia Diagnostics Market to Reach USD 1.33 Billion by 2031

AUSTIN, TEXAS, UNITED STATES, June 24, 2024 /EINPresswire.com/ -- The Global [Preeclampsia Diagnostics Market Size](#) was valued at USD 1.08 billion in 2023 and is projected to reach USD 1.33 billion by 2031, growing at a compound annual growth rate (CAGR) of 2.7% during the forecast period from 2024 to 2031. The steady growth of the market is driven by advancements in diagnostic technologies, increasing awareness about maternal health, and rising incidences of preeclampsia globally.



Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to other organs, most often occurring after 20 weeks of pregnancy. Early detection and management of preeclampsia are crucial to reducing maternal and fetal morbidity and mortality rates. Diagnostic tests for preeclampsia include blood tests, urine analysis, blood pressure monitoring, and ultrasound examinations, aimed at assessing maternal and fetal health during pregnancy.

Key factors contributing to the market growth include the development of more accurate and reliable diagnostic tools, improved screening protocols, and the integration of biomarkers and imaging techniques for early detection and monitoring of preeclampsia. These advancements enable healthcare providers to intervene promptly, manage complications effectively, and optimize maternal and fetal outcomes.

The preeclampsia diagnostics market encompasses a range of diagnostic tests and tools tailored to assess the severity and progression of the condition. Increased research and development activities focused on understanding the pathophysiology of preeclampsia and identifying novel biomarkers contribute to ongoing advancements in diagnostic capabilities.

Download Free Sample Report of Preeclampsia Diagnostics Market @ <https://www.snsinsider.com/sample-request/2993>

Key Takeaways

- Market size: The global preeclampsia diagnostics market is projected to reach USD 1.33 billion by 2031.
- Market Growth: The market is expected to grow at a CAGR of 2.7% from 2024 to 2031.
- Key drivers: Advancements in diagnostic technologies, increasing awareness about maternal health, and rising incidences of preeclampsia.
- Market share by diagnostic method:
 - Blood Tests and Biomarkers: Significant market share due to their accuracy in detecting preeclampsia-related biomarkers.
 - Urine Analysis: Important for monitoring protein levels, a key indicator of kidney function in preeclampsia.
 - Blood Pressure Monitoring: Essential for diagnosing hypertension, a hallmark symptom of preeclampsia.
 - Ultrasound Examinations: Used to assess fetal growth, placental health, and detect signs of complications.
- Challenges: Variability in diagnostic criteria and the need for standardized protocols in preeclampsia diagnosis.
- Regional leader: North America and Europe (due to advanced healthcare infrastructure and proactive screening practices).

Preeclampsia Diagnostics Statistics

- Incidence Rates: Preeclampsia affects approximately 2-8% of pregnancies worldwide, varying by region and demographic factors.
- Maternal Mortality: Preeclampsia is a leading cause of maternal mortality globally, emphasizing the importance of early diagnosis and management.
- Fetal Complications: Preeclampsia increases the risk of premature birth, low birth weight, and intrauterine growth restriction, underscoring the need for comprehensive prenatal care.
- Healthcare Costs: Early diagnosis and management of preeclampsia can lead to significant cost savings by reducing hospitalizations and complications.

Company Recent Developments

- Roche Diagnostics: In January 2024, Roche launched a new panel of biomarkers for preeclampsia diagnostics, enhancing diagnostic accuracy and early intervention strategies.
- Siemens Healthineers: In March 2024, Siemens Healthineers introduced an advanced ultrasound system with enhanced imaging capabilities for assessing maternal and fetal health during pregnancy.
- Abbott Laboratories: In May 2024, Abbott Laboratories expanded its portfolio of diagnostic tests for preeclampsia, focusing on rapid and reliable point-of-care testing solutions.
- PerkinElmer, Inc.: In July 2024, PerkinElmer collaborated with academic institutions to develop

novel genetic markers for predicting preeclampsia risk in early pregnancy stages.

- BD (Becton, Dickinson and Company): In September 2024, BD announced regulatory approval for its automated blood pressure monitoring system, designed specifically for preeclampsia management in clinical settings.

Have Any Query? Ask Our Experts @ <https://www.snsinsider.com/enquiry/2993>

Emerging Trends

- Point-of-Care Testing: Increasing adoption of rapid diagnostic tests for immediate assessment and management of preeclampsia in diverse healthcare settings.
- Digital Health Integration: Integration of digital health platforms to monitor maternal health parameters remotely and enhance patient engagement in prenatal care.
- Artificial Intelligence (AI): AI-driven algorithms for analyzing diagnostic data and predicting preeclampsia risks based on patient-specific factors.
- Personalized Medicine: Tailoring diagnostic approaches and treatment strategies based on individual patient profiles and disease progression.
- Global Health Initiatives: Collaborative efforts to improve maternal health outcomes through standardized screening protocols and access to essential diagnostics in low-resource settings.

Use Cases

- Early Detection: Biomarker panels and genetic tests enable early detection of preeclampsia risks during routine prenatal screenings.
- Monitoring and Management: Regular blood pressure monitoring and urine analysis help healthcare providers monitor disease progression and manage complications.
- Fetal Assessment: Ultrasound examinations assess fetal growth, placental health, and identify signs of intrauterine growth restriction.
- Emergency Response: Rapid diagnostic tests facilitate prompt intervention and emergency management of severe preeclampsia cases.

List of Preeclampsia Diagnostics Companies Profiled in Report:

- Diabetomics Inc.
- PerkinElmer Inc.
- F. Hoffmann-La Roche Ltd.
- DRG Instruments GmbH
- Metabolomic Diagnostics
- Thermo Fisher Scientific Holdings Inc.
- Sera Prognostics Inc.
- Shuwen Biotechnologies Co. Ltd.
- Siemens Healthineers AG
- Baxter
- Others

Key Market Segmentation

By Test Type

- Urine Analysis
- Blood Tests

By Product

- Equipment
- Supplies

By End User

- Hospitals
- Diagnostic facilities
- Speciality clinics
- others

Conclusion

The Global Preeclampsia Diagnostics Market is projected to reach USD 1.33 billion by 2031 from USD 1.08 billion in 2023, growing at a CAGR of 2.7% during 2024-2031. This growth is driven by advancements in diagnostic technologies, increasing awareness about maternal health, and rising incidences of preeclampsia worldwide. Key diagnostic methods include blood tests, urine analysis, blood pressure monitoring, and ultrasound examinations, with North America and Europe leading in market adoption. Challenges in standardizing diagnostic criteria and improving access to diagnostics in low-resource settings remain, underscoring the need for continued innovation and global health initiatives in preeclampsia management.

Purchase Preeclampsia Diagnostics Market Report @

<https://www.snsinsider.com/checkout/2993>

Table of Content

Chapter 1 Introduction

Chapter 2 Research Methodology

Chapter 3 Preeclampsia Diagnostics Market Dynamics

Chapter 4 Impact Analysis (COVID-19, Ukraine- Russia war, Ongoing Recession on Major Economies)

Chapter 5 Value Chain Analysis

Chapter 6 Porter's 5 forces model

Chapter 7 PEST Analysis

Chapter 8 Preeclampsia Diagnostics Market Segmentation, By Test Type

Chapter 9 Preeclampsia Diagnostics Market Segmentation, By Product

Chapter 10 Preeclampsia Diagnostics Market Segmentation, By End User

Chapter 11 Regional Analysis

Chapter 12 Company profile

Chapter 13 Competitive Landscape

Chapter 14 Use Case and Best Practices

Chapter 15 Conclusion
Continued...

Other Trending Reports

[Surgical Robots Market Outlook](#)

[Healthcare EDI Market Outlook](#)

Akash Anand

SNS Insider Pvt. Ltd

+1 415-230-0044

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/722478096>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.